82 citations
,
December 2015 in “Nanomedicine” Nanoparticle systems make cancer treatment less toxic.
18 citations
,
February 2023 in “PLoS ONE” A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.
Researchers made new compounds that could potentially be developed into anticancer drugs.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
7 citations
,
October 2019 in “Annals of palliative medicine” New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
87 citations
,
January 1996 in “Journal of cellular biochemistry” Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
1 citations
,
January 2012 in “Türk jinekoloji ve obstetrik derneði dergisi/Türk Jinekoloji ve Obstetrik Derneği dergisi” Most patients experienced significant but reversible hair loss during treatment.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
20 citations
,
May 2023 in “Cancer Nanotechnology” The new drug delivery system effectively targets lung cancer cells.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
102 citations
,
October 2010 in “Molecular Pharmaceutics” Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
January 2012 in “Journal of Clinical Medicine in Practice” The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.
6 citations
,
July 2025 in “Cancer Medicine” ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
4 citations
,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
7 citations
,
August 2020 in “Current topics in medicinal chemistry” New cancer treatments aim to reduce side effects and improve effectiveness.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
March 2026 in “Pharmaceutics” Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
October 2023 in “Indian Journal of Skin Allergy” Nab-paclitaxel chemotherapy can rarely cause lupus-like skin issues.
Fenugreek seeds and Butea monosperma flowers may help reduce hair loss from chemotherapy.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
More research is needed to understand chemotherapy-induced hair loss and its phases.
21 citations
,
May 1989 in “Advanced Drug Delivery Reviews” Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
August 2025 in “MedScien” Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
April 2025 in “Biological and Clinical Sciences Research Journal” Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.
September 2006 in “Experimental Dermatology” Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.